---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-101176"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2024-09-19T23:59:59+00:00"
generated_at: "2026-05-31T03:40:13.337377+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioXcel Therapeutics reduces workforce by 28% (~15 employees) to cut costs, prioritizes BXCL501; CCO Matt Wiley departs.

## Summary
- Headcount reduction of 28% (~15 employees) approved Sept 17, 2024; charges ~$1.4M primarily in severance and benefits, expected Q4 2024.
- Company prioritizes clinical development of lead neuroscience asset BXCL501 to extend cash runway.
- Chief Commercial Officer Matt Wiley's position eliminated; employment ends Oct 2, 2024, followed by consulting period.
- Company previously identified substantial doubt about going concern; cost reduction aims to extend cash runway.
- Majority of charges expected to be cash expenditures; plan completion by Q4 2024.

## SEC filing metadata
- accession: 0001104659-24-101176
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2024-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465924101176/0001104659-24-101176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465924101176/tm2424352d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-101176
- JSON: https://secwatch.observer/filing/0001104659-24-101176.json
- Plain text: https://secwatch.observer/filing/0001104659-24-101176.txt

## Key facts
- Executive change
  Matt Wiley departed as Chief Commercial Officer at BioXcel Therapeutics, Inc..
  - Action: position eliminated
  - Role: Chief Commercial Officer
  source text: On September 18, 2024, the Company notified Matt Wiley, the Company’s Chief Commercial Officer, that, in connection with the Clinical Prioritization, his position was being eliminated.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465924101176/0001104659-24-101176-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.